Standardized management of tyrosine kinase inhibitors therapy for patients with chronic myelogenous leukemia in clinic

Clinical Focus ›› 2015, Vol. 30 ›› Issue (10): 1104-1109.

Previous Articles Next Articles

Standardized management of tyrosine kinase inhibitors therapy for patients with chronic myelogenous leukemia in clinic

Guo Xiaonan;Qiao Shukai

Online:2015-10-05 Published:2015-10-05

Abstract

CLC Number:

R733.712

Guo Xiaonan;Qiao Shukai. Standardized management of tyrosine kinase inhibitors therapy for patients with chronic myelogenous leukemia in clinic[J]. Clinical Focus, 2015, 30(10): 1104-1109.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/

https://huicui.hebmu.edu.cn/EN/Y2015/V30/I10/1104

[1]	Li Shufan, Wang Yuxiu, Jiang Zhenghua. The correlation between the prognosis of lung adenocarcinoma with acquired resistance to the first-generation EGFR TKI and the T790M mutation [J]. Clinical Focus, 2022, 37(11): 985-991.
[2]	He Yiwen, Qiao Tiankui. Clinical value of CEA, CA125, and CYFRA21-1 levels in efficacy evaluation of EGFR-TKIs in the treatment of EGFR mutation-positive non-small cell lung adenocarcinoma [J]. Clinical Focus, 2021, 36(3): 220-224.
[3]	Lyu Cuicui, Li Xin, Li Qing, Mu Juan, Wang Jia, Yuan Ting, Jiang Yanyu, Deng Qi. Influence of TKIs on proliferation of CD19 CAR-T cells in refractory/relapsed Ph+ acute lymphoblastic leukemia [J]. Clinical Focus, 2020, 35(10): 909-913.

Standardized management of tyrosine kinase inhibitors therapy for patients with chronic myelogenous leukemia in clinic

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 3

Recommended Articles

Metrics

Comments